Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma



Status:Recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/24/2019
Start Date:August 10, 2017
End Date:December 31, 2022

Use our guide to learn which trials are right for you!

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

This randomized phase II trial studies how well obinutuzumab with or without umbralisib,
lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa
follicular lymphoma that has come back or does not respond to treatment. Immunotherapy with
monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the
cancer, and may interfere with the ability of the tumor cells to grow and spread. Umbralisib
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Biological therapies, such as lenalidomide, use substances made from living organisms that
may stimulate or suppress the immune system in different ways and stop cancer cells from
growing. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride,
vincristine sulfate, prednisone, and bendamustine, work in different ways to stop the growth
of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. It is not yet known whether giving obinutuzumab with or without
umbralisib, lenalidomide, or combination chemotherapy will work better in treating patients
with grade I-IIIa follicular lymphoma.

PRIMARY OBJECTIVES:

I. To compare the complete response rate at 6 cycles after randomization as defined by
centrally read positron emission tomography (PET)/computed tomography (CT) (integral
biomarker) of 2 targeted therapeutic regimens (obinutuzumab + umbralisib [TGR-1202] or
obinutuzumab + lenalidomide) with obinutuzumab + chemotherapy (cyclophosphamide, doxorubicin
hydrochloride, vincristine sulfate, and prednisone [CHOP] or bendamustine) in patients with
early relapsing or refractory follicular lymphoma.

SECONDARY OBJECTIVES:

I. To validate the prognostic association of the m7-FLIPI model, demonstrating that the
population of follicular lymphoma patients who respond poorly to chemoimmunotherapy are
enriched for having a high-risk m7-FLIPI score, and that the score is associated with
progression-free survival (integrated biomarker). (Primary translational medicine) II. To
estimate the 30-month sustained complete response rate (CR30) defined by centrally read
PET/CT with each of the regimens in this early relapsing or refractory follicular lymphoma
population.

III. To estimate best response at 12 cycles of therapy, progression free survival, duration
of response and overall survival with each of the combinations in early relapsing or
refractory follicular lymphoma.

IV. To evaluate the adverse effects of each of the regimens in early relapsing or refractory
follicular lymphoma.

V. To evaluate the predictive performance of non-invasive genotyping (m7-FLIPI in circulating
tumor deoxyribonucleic acid [DNA]) of plasma at study entry relative to standard tumor
genotyping (m7-FLIPI) of formalin-fixed paraffin-embedded tumor tissue.

VI. To evaluate the association between the detection of active lymphoma by PET-CT and the
detection of circulating tumor DNA in plasma at baseline, after 6 and 12 cycles, and at 30
months after initiation of study therapy.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: Patients receive obinutuzumab intravenously (IV) on day 1 and umbralisib orally (PO)
daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of
disease progression or unacceptable toxicity.

ARM II: Patients receive obinutuzumab IV on day 1 and lenalidomide PO on days 1-21. Treatment
repeats every 28 days for up 12 courses in the absence of disease progression or unacceptable
toxicity.

ARM III:

PRIOR BENDAMUSTINE-BASED CHEMOTHERAPY: Patients receive obinutuzumab IV on day 1,
cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV
on day 1, and prednisone PO on days 1-5. Treatment with obinutuzumab repeats every 21 or 28
days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Treatment with combination chemotherapy repeats every 21 days for 6 courses in the absence of
disease progression or unacceptable toxicity.

PRIOR CHOP CHEMOTHERAPY: Patients receive obinutuzumab IV on day 1, and bendamustine IV over
60 minutes on days 1 and 2. Treatment repeats every 28 days for up to 6 or 12 courses
(bendamustine and obinutuzumab, respectively) in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and
then every 6 months for 3 years.

Inclusion Criteria:

- Patients must have follicular lymphoma (grade I, II or IIIa) confirmed at initial
diagnosis and at relapse with identifiable fludeoxyglucose F-18 (FDG) avid disease on
PET/CT; patients that have involvement with large cell lymphoma are not eligible

- Patients must not have clinical evidence of central nervous system involvement by
lymphoma since the proposed treatment strategies are not designed to address central
nervous system (CNS) involvement adequately; if performed, any laboratory or
radiographic tests performed to assess CNS involvement must be negative

- Patients must have a whole body or limited whole body PET/CT scan performed within 42
days prior to registration

- Patients must have bone marrow biopsy performed within 42 days prior to registration

- All disease must be assessed and documented on the S1608 FDG-PET/CT assessment form

- Patients must have either failed to achieve a complete remission, or must have
relapsed within 2 years after completing CHOP or bendamustine-containing
chemoimmunotherapy (including an anti-CD20 monoclonal antibody), as measured from the
last dose of CHOP or bendamustine; relapsed patients must not have received any
intervening chemotherapy; patients must have received only 1 course of chemotherapy,
containing at least 3 cycles of CHOP or bendamustine; (note that no minimum dose of
bendamustine is required); patients who received any anti-CD20 antibody therapy prior
to CHOP or bendamustine are eligible; patients who additionally received any
maintenance anti-CD-20 antibody therapy or consolidative radioimmunotherapy within 2
years of the last dose of the CHOP or bendamustine therapy are eligible; involved
field or involved site radiation is not considered a line of therapy; examples of
eligible prior treatment regimens (note this list is not all inclusive):

- 1st line rituximab treatment followed years later by bendamustine rituximab x 4
cycles

- Bendamustine rituximab x 4 cycles

- 1st line rituximab treatment, 2nd line ibritumomab tiuxetan, followed by
bendamustine bortezomib rituximab x 6 cycles followed by rituximab maintenance

- Bendamustine obinutuzumab x 3 cycles

- CHOP rituximab x 6 cycles followed by rituximab maintenance

- For all forms of systemic therapy, patients must have completed therapy at least 21
days prior to registration; patients must have completed any radioimmunotherapy at
least 84 days prior to registration; patients must have recovered from all treatment
related toxicities from these therapies prior to registration

- Patients must not have any prior treatment with any PI3K inhibitor, or lenalidomide

- Patients must have tissue specimens collected prior to registration; patients must be
offered participation in biobanking of residual specimens; with patient consent,
residuals from the mandatory submission will be banked for future research

- All patients must have a Zubrod performance status of 0, 1 or 2

- Absolute neutrophil count (ANC) >= 1,500/mcL within 28 days prior to registration

- Platelets >= 75,000/mcL within 28 days prior to registration

- Patients must have adequate renal function as documented by a calculated creatinine
clearance >= 60 mL/min, within 28 days prior to registration

- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (=< 5 x IULN if
secondary to lymphoma, Gilbert's syndrome, or medication related [e.g., indinavir,
tenofovir, atazanavir]) within 28 days prior to registration

- Direct bilirubin =< 1.5 x IULN (=< 5 x IULN if secondary to lymphoma) within 28 days
prior to registration

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (=<
5 x IULN secondary to lymphoma) within 28 days prior to registration

- Patients must have an echocardiogram (ECHO) or multigated acquisition (MUGA) scan
within 42 days prior to registration with a cardiac ejection fraction >= 45%

- Patients with hepatitis B virus infection must have undetectable hepatitis B virus
(HBV) on suppressive therapy and no evidence of HBV-related hepatic damage; patients
with hepatitis C virus infection are eligible if complete eradication therapy has been
successfully completed, and there is no detectable hepatitis C virus (HVC) or related
hepatic damage; patients with known human immunodeficiency virus (HIV) infection are
eligible if they meet all of the following criteria in addition to the other protocol
eligibility criteria:

- Patient must have no history of acquired immune deficiency syndrome
(AIDS)-related complications, other than a history of low CD4+ T-cell count (<
200/mm^3) prior to initiation of combination antiretroviral therapy; on study
CD4+ T-cell count may not be informative due to leukemia and should not be used
as an exclusion criterion if low

- Patient must be healthy on the basis of HIV disease with high likelihood of near
normal life span were it not for the leukemia

- Patient must have serum HIV viral load of < 200 copies/mm^3

- Patient must be on combination antiretroviral therapy with minimal
pharmacokinetic interactions with study therapy and minimal overlapping clinical
toxicity with protocol therapy; (recommend a regimen of the integrase inhibitor
dolutegravir combined with either disoproxil fumarate/emtricitabine or
dolutegravir combined with tenofovir alafenamide/emtricitabine)

- Protease inhibitors and once daily formulations containing cobicistat are NOT
allowed due to potential pharmacokinetic interactions with leukemia therapy

- Stavudine and zidovudine (AZT) are NOT allowed because of overlapping toxicity
with protocol therapy

- Patients must be able and willing to receive prophylaxis with daily aspirin, low
molecular weight heparin, factor X inhibitors or warfarin if randomized to
lenalidomide; patients must also be willing to receive pneumocystis jirovecii
prophylaxis with sulfamethoxazole/trimethoprim, dapsone, atovaquone or inhaled
pentamidine, in the event that they are randomized to TGR-1202; patients unable or
unwilling to take any listed prophylaxis are NOT eligible

- Patients must be able to discontinue CYP2C9 substrates with a narrow therapeutic index
(e.g. warfarin, phenytoin), if randomized to TGR-1202; patients must discontinue such
agents at least 1 week or 5 half-lives prior to beginning protocol therapy (whichever
is longer)

- No second prior malignancy is allowed except for adequately treated basal (or squamous
cell) skin cancer, in situ cervical cancer or other cancer for which the patient has
been disease free for three years

- Patients must have a complete history and physical examination within 28 days prior to
registration

- Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
test with a sensitivity of at least 25 mIU/mL within 10-14 days and again within 24
hours prior to starting cycle 1 of lenalidomide; further, they must either commit to
complete abstinence (true abstinence is acceptable when this is in line with the
preferred and usual lifestyle of the subject; periodic abstinence [e.g., calendar,
ovulation, symptothermal or post ovulation methods] and withdrawal are not acceptable
methods of contraception) from heterosexual intercourse or begin TWO acceptable
methods of birth control: one highly effective method and one additional effective
method AT THE SAME TIME, at least 28 days before starting lenalidomide; while taking
lenalidomide, during dose interruptions, and for at least 28 days after the last dose
of lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to
use a latex condom during sexual contact with a FCBP, even if they have had a
successful vasectomy; a FCBP is a female who: 1) has achieve menarche at some point;
2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been
naturally postmenopausal (amenorrhea following cancer therapy does not rule out
childbearing potential) for at least 24 consecutive months (i.e., has had menses at
any time in the preceding 24 consecutive months); all patients must be counseled by a
trained counselor every 28 days about pregnancy precautions and risks of fetal
exposure; NOTE: patients not randomized to receive lenalidomide will not be required
to undergo serial pregnancy testing or lenalidomide counseling after registration

- Patients must have lactate dehydrogenase (LDH) and beta-2-microglobulin collected
within 28 days prior to registration

- Patients must be informed of the investigational nature of this study and must sign
and give written informed consent in accordance with institutional and federal
guidelines

- As a part of the OPEN registration process the treating institution's identity is
provided in order to ensure that the current (within 365 days) date of institutional
review board approval for this study has been entered in the system
We found this trial at
347
sites
27472 Schoenherr Road
Warren, Michigan 48088
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Warren, MI
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Matthew Fero
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
Principal Investigator: Alex F. Herrera
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
300 Community Drive
Manhasset, New York 11030
(516) 562-0100
Principal Investigator: Sadia Riaz
Phone: 516-734-8896
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Mazyar Shadman
Phone: 800-804-8824
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Mazyar Shadman
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Anaheim, California 92806
Principal Investigator: Lara N. Durna
Phone: 800-398-3996
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Tycel J. Phillips
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Arroyo Grande, CA
Click here to add this to my saved trials
1625 Maple Lane
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
?
mi
from
Ashland, WI
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Christopher R. Flowers
Phone: 404-778-1868
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Edmund W. Tai
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Baldwin Park, California 91706
Principal Investigator: Lara N. Durna
Phone: 800-398-3996
?
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Baton Rouge, Louisiana 70806
Principal Investigator: Hana F. Safah
Phone: 225-381-6451
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Baton Rouge, Louisiana 70806
Principal Investigator: Hana F. Safah
Phone: 225-767-0822
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Lara N. Durna
Phone: 800-398-3996
?
mi
from
Bellflower, CA
Click here to add this to my saved trials
Bemidji, Minnesota 56601
Principal Investigator: Preston D. Steen
Phone: 218-333-5000
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Edmund W. Tai
Phone: 415-209-2686
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Billings, MT
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bolivar, Missouri 65613
Principal Investigator: Rakesh Gaur
Phone: 800-328-6010
?
mi
from
Bolivar, MO
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Boulder, CO
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
Brownstown, Michigan 48183
Principal Investigator: Ding Wang
Phone: 313-916-3721
?
mi
from
Brownstown, MI
Click here to add this to my saved trials
130 S Bryn Mawr Ave
Bryn Mawr, Pennsylvania 19010
(484) 337-3000
Principal Investigator: Albert S. DeNittis
Phone: 484-476-2649
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
?
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Gary E. Goodman
Phone: 818-847-4793
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Tarun Kewalramani
Phone: 781-744-8027
?
mi
from
Burlington, MA
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
406-723-2500
Principal Investigator: Keren Sturtz
Phone: 406-723-2621
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
?
mi
from
Butte, MT
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Carson City, NV
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Brian T. Hess
Phone: 843-792-9321
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
3110 MacCorkle Avenue Southeast
Charleston, West Virginia 25304
Principal Investigator: Steven J. Jubelirer
Phone: 304-388-9944
?
mi
from
Charleston, WV
Click here to add this to my saved trials
Charlotte, North Carolina 28204
Principal Investigator: Nilanjan Ghosh
Phone: 800-804-9376
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
14650 East Old US Highway 12
Chelsea, Michigan 48118
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Sonali M. Smith
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Jane N. Winter
Phone: 312-695-1301
?
mi
from
Chicago, IL
Click here to add this to my saved trials
12961 27th Ave
Chippewa Falls, Wisconsin 54729
715-738-3700
Principal Investigator: Bilal H. Naqvi
Phone: 800-782-8581
Marshfield Clinic - Chippewa Center The 15,000 square foot Lake Hallie Center provides urgent care...
?
mi
from
Chippewa Falls, WI
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45255
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45247
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
9280 SE Sunnybrook Blvd #100
Clackamas, Oregon 97015
(503) 513-3300
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Clackamas Radiation Oncology Center State-of-the-art technology and compassionate care come together at Clackamas Radiation Oncology...
?
mi
from
Clackamas, OR
Click here to add this to my saved trials
Clackamas, Oregon 97015
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
?
mi
from
Clackamas, OR
Click here to add this to my saved trials
2500 Metrohealth Dr
Cleveland, Ohio 44109
(216) 778-7800
Principal Investigator: Bruce J. Averbook
Phone: 216-778-8526
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clinton, North Carolina 28328
Principal Investigator: Nagesh H. Jayaram
Phone: 919-587-9077
?
mi
from
Clinton, NC
Click here to add this to my saved trials
Clinton Township, Michigan 48038
Principal Investigator: Ding Wang
Phone: 313-916-3721
?
mi
from
Clinton Township, MI
Click here to add this to my saved trials
12495 University Ave
Clive, Iowa 50325
(515) 358-9700
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Cancer Center - West Lakes When it comes to cancer care, there
?
mi
from
Clive, IA
Click here to add this to my saved trials
Clive, Iowa 50325
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Clive, IA
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Colorado Springs, Colorado 80907
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Kami J. Maddocks
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Columbus, Ohio 43213
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
(614) 566-5000
Principal Investigator: Timothy D. Moore
Phone: 614-566-4475
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3100 Plaza Properties Blvd
Columbus, Ohio 43219
(614) 383-6000
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
The Mark H. Zangmeister Center At The Zangmeister Center, we appreciate that our patients have...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
810 Jasonway Avenue
Columbus, Ohio 43214
614/442-3130
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
Columbus Oncology and Hematology Associates Inc Columbus Oncology and Hematology Associates is a group of...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Columbus, Ohio 43222
Principal Investigator: Timothy D. Moore
Phone: 614-234-5433
?
mi
from
Columbus, OH
Click here to add this to my saved trials
4050 Coon Rapids Blvd NW
Coon Rapids, Minnesota 55433
(763) 236-6000
Principal Investigator: David M. King
Phone: 952-993-1517
Mercy Hospital Mercy Hospital, located in Coon Rapids, Minnesota, is a 271-bed non-profit hospital that...
?
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Coos Bay, Oregon 97420
Principal Investigator: Gary E. Goodman
Phone: 541-269-8392
?
mi
from
Coos Bay, OR
Click here to add this to my saved trials
Danville, Illinois 61832
Principal Investigator: Priyank P. Patel
Phone: 800-446-5532
?
mi
from
Danville, IL
Click here to add this to my saved trials
1 Wyoming St,
Dayton, Ohio 45409
(937) 208-8000
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Miami Valley Hospital Miami Valley Hospital (MVH) is passionate about providing the most recent medical...
?
mi
from
Dayton, OH
Click here to add this to my saved trials
2222 Philadelphia Dr
Dayton, Ohio 45406
(937) 734-2612
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Good Samaritan Hospital - Dayton Good Samaritan Hospital (GSH) is passionate about providing the most...
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Dayton, Ohio 45415
Principal Investigator: Howard M. Gross
Phone: 937-832-1093
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Dearborn, Michigan 48126
Principal Investigator: Ding Wang
Phone: 313-916-3721
?
mi
from
Dearborn, MI
Click here to add this to my saved trials
Dearborn, Michigan 48124
Principal Investigator: Christopher M. Reynolds
Phone: 313-593-8090
?
mi
from
Dearborn, MI
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
?
mi
from
Decatur, IL
Click here to add this to my saved trials
210 West McKinley Avenue
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Decatur, IL
Click here to add this to my saved trials
777 Bannock St
Denver, Colorado 80204
(303) 436-6000
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Denver Health Medical Center Denver Health is a comprehensive, integrated organization providing level one care...
?
mi
from
Denver, CO
Click here to add this to my saved trials
4567 E 9th Ave
Denver, Colorado 80220
(303) 320-2121
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Rose Medical Center Well known as a Denver institution and a 9th Avenue landmark for...
?
mi
from
Denver, CO
Click here to add this to my saved trials
2525 S Downing St
Denver, Colorado 80210
(303) 778-1955
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Porter Adventist Hospital Founded in 1930, Porter Adventist Hospital has provided people throughout Denver and...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials
1721 East 19th Ave., Suite #200 & #300
Denver, Colorado 80218
720-754-4800
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Colorado Blood Cancer Institute When patients come to the Colorado Blood Cancer Institute, the entire...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80220
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials